Mucopolysaccharidosis I Clinical Trial
Official title:
A Phase 4, Single-arm, Open-label Safety and Efficacy Study of Aldurazyme® (Laronidase) as Enzyme Replacement Therapy in Participants With Mucopolysaccharidosis I (MPS I) in China
This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I. Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants. Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).
Study duration for each participant will be a total of 29 weeks which will include 2 weeks of screening, 26 weeks of treatment period and 1 week of follow-up period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01675674 -
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
|
N/A | |
| Completed |
NCT00741338 -
Immune Tolerance Study With Aldurazyme® (Laronidase)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT04227600 -
A Study of JR-171 in Patients With Mucopolysaccharidosis I
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04453085 -
An Extension Study of JR-171-101 Study in Patients With MPS I
|
Phase 1/Phase 2 | |
| Terminated |
NCT00418821 -
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
|
Phase 4 | |
| Completed |
NCT03071341 -
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
|
Phase 1/Phase 2 | |
| Completed |
NCT03053089 -
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
|
Phase 1/Phase 2 | |
| Completed |
NCT00146757 -
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old
|
Phase 2 | |
| Active, not recruiting |
NCT04628871 -
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
|
||
| Completed |
NCT02597114 -
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
|
Phase 1 | |
| Terminated |
NCT00748969 -
Clinical Trial of Growth Hormone in MPS I, II, and VI
|
Phase 2/Phase 3 | |
| Terminated |
NCT00215527 -
Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I
|
Phase 1 | |
| Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
| Completed |
NCT00146770 -
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
|
Phase 3 | |
| Completed |
NCT00176917 -
Stem Cell Transplantation for Hurler
|
Phase 2 | |
| Completed |
NCT00176891 -
Stem Cell Transplant w/Laronidase for Hurler
|
Phase 2 | |
| Active, not recruiting |
NCT03153319 -
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
|
Phase 1/Phase 2 | |
| Completed |
NCT00852358 -
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
|
N/A | |
| Enrolling by invitation |
NCT06103487 -
Long Term Follow-Up for RGX-111
|